ERBB2 and neoplasm: Approximately 15% of invasive breast cancers (BCs) are human epidermal growth factor receptor2 (HER2) positive, defined as showing HER2 gene amplification or protein overexpression, and such tumours have been shown to be sensitive to anti-HER2 targeted therapy [1–3].